“Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials”, J of Skin, vol. 5, no. 1, p. s20, Jan. 2021, doi: 10.25251/skin.5.supp.20.